Minimizing intestinal dysfunction

Patent metadata

Field	Value
Publication number	US-9962432-B2
Application number	US-201615044356-A
Country	US
Kind code	B2
Filing date	Feb 16, 2016
Priority date	Oct 2, 2010
Publication date	May 8, 2018
Grant date	May 8, 2018

Abstract

Techniques are disclosed for treating or reducing symptoms associated with abdominal dysfunction or ileus following surgery or other abdominal episode by treating the area with a combination of one or more protease, antibacterial compound, and inflammatory lipid mediator.

First claim

What is claimed is:

1. A method for treating ileus, the method comprising:
administering to an individual a therapeutic dose of:
an inhibitor of a degrading enzyme, wherein the inhibitor of a degrading enzyme is cyclokapron at a dose of 10 to 50 mg/100 ml;
an antibacterial compound; and
an inflammatory lipid mediator binding protein.

2. The method of claim 1 , wherein the antibacterial compound is effective against gram-positive and gram-negative bacteria.

3. The method of claim 2 , wherein the antibacterial compound includes one or more of ciprofloxacin, metronidazole, imipenem, cilastatin, ticarcillin, clavulanate, cefuroxime, and doxycycline.

4. The method of claim 1 , wherein the inflammatory lipid mediator binding protein is selected from the group consisting of albumin and free fatty acid binding proteins.

5. The method of claim 4 , wherein the dose of inflammatory lipid mediator binding protein is 10 to 50 mg/100 ml.

6. The method of claim 1 , wherein the administering step is prophylactically into the abdominal cavity.

7. A method for treating abdominal dysfunction, the method comprising:
administering to an individual a therapeutic dose of:
an inhibitor of a degrading enzyme, wherein the degrading enzyme is cyclokapron with a dose of 10 to 50 mg/100 ml;
an antibacterial compound; and
an inflammatory lipid mediator binding protein.

8. The method of claim 7 , wherein the antibacterial compound is effective against gram-positive and gram-negative bacteria.

9. The method of claim 8 , wherein the antibacterial compound includes one or more of ciprofloxacin, metronidazole, imipenem, cilastatin, ticarcillin, clavulanate, cefuroxime, and doxycycline.

10. The method of claim 7 , wherein the inflammatory lipid mediator binding protein is selected from the group consisting of albumin and free fatty acid binding proteins.

11. The method of claim 10 , wherein the dose of inflammatory lipid mediator binding protein is 10 to 50 mg/100 ml.

12. The method of claim 7 , wherein the administering step is prophylactically into the abdominal cavity.

13. A method for treating ileus, the method comprising:
administering to an individual a therapeutic dose of:
an inhibitor of a degrading enzyme, wherein the degrading enzyme is a serine protease, a plasma protease, an MMP, an amylase or a lipase;
an antibacterial compound; and
an inflammatory lipid mediator binding protein, wherein the inflammatory lipid mediator binding protein is selected from the group consisting of albumin and free fatty acid binding proteins at a dose of 10 to 50 mg/100 ml.

14. The method of claim 13 , wherein the inhibitor of a degrading enzyme is cyclokapron.

15. The method of claim 13 , wherein the antibacterial compound includes one or more of ciprofloxacin, metronidazole, imipenem, cilastatin, ticarcillin, clavulanate, cefuroxime, and doxycycline.

16. The method of claim 13 , wherein the administering step is prophylactically into the abdominal cavity.

17. A method for treating abdominal dysfunction, the method comprising:
administering to an individual a therapeutic dose of:
an inhibitor of a degrading enzyme, wherein the degrading enzyme is a serine protease, a plasma protease, an MMP, an amylase or a lipase;
an antibacterial compound; and
an inflammatory lipid mediator binding protein, wherein the inflammatory lipid mediator binding protein is selected from the group consisting of albumin and free fatty acid binding proteins at a dose of 10 to 50 mg/100 ml.

18. The method of claim 17 , wherein the inhibitor of a degrading enzyme is cyclokapron.

19. The method of claim 17 , wherein the antibacterial compound includes one or more of ciprofloxacin, metronidazole, imipenem, cilastatin, ticarcillin, clavulanate, cefuroxime, and doxycycline.

20. The method of claim 17 , wherein the administering step is prophylactically into the abdominal cavity.

Assignees

• Univ California

Inventors

• Delano Frank A
• Schmid-Schoenbein Geert W
• Saltzman Darin

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/496

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title